Prostanoid and isoprostanoid pathways in atherogenesis

被引:45
作者
Pratico, Domenico [1 ]
机构
[1] Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA
关键词
Atherosclerosis; Prostaglandin; Oxidative stress; Inflammation;
D O I
10.1016/j.atherosclerosis.2008.04.037
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atherosclerosis is it chronic inflammatory disease of the vasculature that is influenced by multiple factors and involves a complex interplay between some components of the bloodstream and the arterial wall. Among different circulating factors implicated in atherogenesis there is a large group of bioactive lipids called prostanoids and isoprostanoids. Prostanoids are formed via the enzymatic oxidation of arachidonic acid, and the various sub-classes are generated by distinct enzymatic pathways. Isoprostanoids represent a class of prostanoid isomers formed via a free radical-mediated oxidation of fatty acids esterified in membrane phospholipids. Both groups of lipids manifest their biologic activities by binding to specific receptors in target cells. In recent years, a lot of research effort has been focused on these lipid mediators because of their active roles in cardiovascular physiology, and because their biosynthesis is severely altered in patients with atherosclerosis. This review article describes the biological roles that prostanoids, isoprostanoids and their receptors play in atherogenesis by integrating our current knowledge of basic cellular mechanisms with the results of experimental genetic and pharmacologic studies using modulators of these pathways. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:8 / 16
页数:9
相关论文
共 82 条
[1]  
Aschoff L., 1933, ARTERIOSCLEROSIS SUR, P1
[2]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[3]  
BAILEY JM, 1973, ATHEROSCLEROSIS, V17, P515
[4]   Activation of thromboxane receptor upregulates interleukin (IL)-1β-induced VCAM-1 expression through JNK signaling [J].
Bayat, Hossein ;
Xu, Shanqin ;
Pimentel, David ;
Cohen, Richard A. ;
Jiang, Bingbing .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (01) :127-134
[5]   Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis [J].
Bea, F ;
Blessing, E ;
Bennett, BJ ;
Kuo, CC ;
Campbell, LA ;
Kreuzer, J ;
Rosenfeld, ME .
CARDIOVASCULAR RESEARCH, 2003, 60 (01) :198-204
[6]   Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin [J].
Belhassen, L ;
Pelle, G ;
Dubois-Rande, JL ;
Adnot, S .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (07) :1198-1204
[7]  
Belton O, 2000, CIRCULATION, V102, P840
[8]   Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis [J].
Belton, OA ;
Duffy, A ;
Toomey, S ;
Fitzgerald, DJ .
CIRCULATION, 2003, 108 (24) :3017-3023
[9]   Fibrinolysis and cardiovascular risk factors:: Association with fibrinogen, lipids, and monocyte count [J].
Boudjeltia, Karim Zouaoui ;
Guillaume, Michel ;
Henuzet, Charles ;
Delree, Paul ;
Cauchie, Philippe ;
Remacle, Claude ;
Ducobu, Jean ;
Vanhaeverbeek, Michel ;
Brohee, Dany .
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2006, 17 (02) :102-108
[10]   Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice [J].
Burleigh, ME ;
Babaev, VR ;
Oates, JA ;
Harris, RC ;
Gautam, S ;
Riendeau, D ;
Marnett, LJ ;
Morrow, JD ;
Fazio, S ;
Linton, MF .
CIRCULATION, 2002, 105 (15) :1816-1823